Genotoxic Impurities in Pharmaceutical Raw Materials and Their Impact on Product Quality

Genotoxic impurities (GTIs) are DNA-reactive substances that pose serious health risks, including mutagenesis and carcinogenesis, even at trace levels. Their presence in pharmaceutical raw materials has become a critical concern for drug safety and product quality. This paper explores the historical development of GTI monitoring, from early oversight in impurity control to the emergence of stringent international guidelines like ICH M7. It examines common sources of GTIs, analytical techniques for their detection, and regulatory frameworks for their control. The paper also discusses the significant impact of GTIs on manufacturing complexity, regulatory compliance, and patient safety. Recent crises, such as nitrosamine contamination in widely used drugs, have underscored the importance of robust GTI risk assessment, analytical validation, and quality-by-design approaches. Looking forward, technological innovations and global harmonization continue to shape the future of GTI management in pharmaceutical development.